Literature DB >> 6403631

Use of an enzyme-linked immunosorbent assay technique in the differential diagnosis of active pulmonary tuberculosis in humans.

S B Kalish, R C Radin, J P Phair, D Levitz, C R Zeiss, E Metzger.   

Abstract

Sera from patients with active pulmonary tuberculosis and pulmonary diseases frequently mimicking tuberculosis were assayed for immunoglobulin G antibody activity to purified protein derivative (PPD) by an enzyme-linked immunosorbent assay. A method of standardization was developed to limit assay variation. Patients with active pulmonary tuberculosis had a significantly greater mean level of antibody than had patients with atypical tuberculosis (P = 0.005), sarcoidosis (P = 0.0001), histoplasmosis (P = 0.004), blastomycosis (P = 0.008), or cryptococcosis (P = 0.017), patients who had received bacille Calmette-Guérin vaccination (P = 0.003) or who had a history of treated tuberculosis (P = 0.003), and PPD skin test-positive and skin test-negative control subjects (P = 0.001). This technique may have potential use as a rapid diagnostic aid in evaluating patients with suspected active pulmonary tuberculosis.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6403631     DOI: 10.1093/infdis/147.3.523

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

1.  The pattern of mycobacterial antigen recognition in sera from Mantoux-negative individuals is essentially unaffected by bacille Calmette-Guérin (BCG) vaccination in either south India or London.

Authors:  S Das; S H Cheng; D B Lowrie; K B Walker; D A Mitchison; R S Vallishayee; P R Narayanan
Journal:  Clin Exp Immunol       Date:  1992-09       Impact factor: 4.330

Review 2.  Diagnosis of neurotuberculosis.

Authors:  N M Wagle; A K Vaidya
Journal:  Indian J Pediatr       Date:  1990 Sep-Oct       Impact factor: 1.967

3.  Identification of Mycobacterium tuberculosis antigens in Seibert fractions by immunoblotting.

Authors:  S R Coates; D Hansen; G Schecter; G Slutkin; P Hopewell; L Affronti; D F Echenberg
Journal:  J Clin Microbiol       Date:  1986-07       Impact factor: 5.948

4.  Enzyme immunoassay using BCG in serodiagnosis of pulmonary tuberculosis.

Authors:  F L Garcia-Carreño; R E Carvajal; R Hernandez
Journal:  J Hyg (Lond)       Date:  1986-12

5.  Performance of a lateral flow immunochromatography test for the rapid diagnosis of active tuberculosis in a large multicentre study in areas with different clinical settings and tuberculosis exposure levels.

Authors:  Selene Manga; Rocio Perales; Maria Reaño; Lia D'Ambrosio; Giovanni Battista Migliori; Massimo Amicosante
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

6.  Determination of mycobacterial antigens in sputum by enzyme immunoassay.

Authors:  M A Yáñez; M P Coppola; D A Russo; E Delaha; S D Chaparas; H Yeager
Journal:  J Clin Microbiol       Date:  1986-05       Impact factor: 5.948

7.  Improved serodiagnosis of tuberculosis using two assay test.

Authors:  E Krambovitis; M Harris; D T Hughes
Journal:  J Clin Pathol       Date:  1986-07       Impact factor: 3.411

8.  Identification of B- and T-cell epitopes within the MTP40 protein of Mycobacterium tuberculosis and their correlation with the disease course.

Authors:  J C Falla; C A Parra; M Mendoza; L C Franco; F Guzmán; J Forero; O Orozco; M E Patarroyo
Journal:  Infect Immun       Date:  1991-07       Impact factor: 3.441

9.  Serodiagnosis of pulmonary tuberculosis in Argentina by enzyme-linked immunosorbent assay (ELISA) of IgG antibody to Mycobacterium tuberculosis antigen 5 and tuberculin purified protein derivative.

Authors:  E A Balestrino; T M Daniel; M D de Latini; O A Latini; Y Ma; J B Scocozza
Journal:  Bull World Health Organ       Date:  1984       Impact factor: 9.408

10.  PPE antigen Rv2430c of Mycobacterium tuberculosis induces a strong B-cell response.

Authors:  Rakesh Kumar Choudhary; Sangita Mukhopadhyay; Prachee Chakhaiyar; Naresh Sharma; K J R Murthy; V M Katoch; Seyed E Hasnain
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.